{
    "ticker": "MIR",
    "name": "Mirati Therapeutics, Inc.",
    "description": "Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for cancer patients. Founded in 2010 and headquartered in San Diego, California, Mirati aims to transform the treatment landscape of cancer through its specialized approach to precision medicine. The company is particularly known for its pioneering work in targeted therapies, specifically those addressing genetic mutations that drive cancer progression. Mirati's lead product, Krazati (adagrasib), is designed to target KRAS G12C mutations, which are prevalent in various cancer types, including non-small cell lung cancer (NSCLC). Additionally, Mirati is advancing a robust pipeline of investigational therapies that target other genetic and epigenetic drivers of cancer, including those involved in DNA damage repair mechanisms. Mirati's commitment to scientific innovation is underscored by its collaborations with leading academic institutions and participation in global clinical trials, aiming to provide patients with more effective treatment options. The company's vision is to redefine cancer treatment and improve patient outcomes by leveraging cutting-edge research and development in oncology.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2010",
    "website": "https://www.miratitx.com",
    "ceo": "Charles M. Baum",
    "social_media": {
        "twitter": "https://twitter.com/miratitx",
        "linkedin": "https://www.linkedin.com/company/mirati-therapeutics"
    },
    "investor_relations": "https://investors.miratitx.com",
    "key_executives": [
        {
            "name": "Charles M. Baum",
            "position": "CEO"
        },
        {
            "name": "Michael A. Taylor",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Krazati (adagrasib)"
            ]
        }
    ],
    "seo": {
        "meta_title": "Mirati Therapeutics, Inc. | Innovative Cancer Therapies",
        "meta_description": "Explore Mirati Therapeutics, Inc., a leader in precision medicine focused on developing targeted therapies for cancer. Discover their innovative pipeline and commitment to transforming oncology.",
        "keywords": [
            "Mirati Therapeutics",
            "Cancer Therapy",
            "Precision Medicine",
            "Biotechnology",
            "KRAS G12C",
            "Oncology"
        ]
    },
    "faq": [
        {
            "question": "What is Mirati Therapeutics known for?",
            "answer": "Mirati Therapeutics is known for its development of innovative targeted therapies for cancer, particularly treatments aimed at specific genetic mutations."
        },
        {
            "question": "Who is the CEO of Mirati Therapeutics?",
            "answer": "Charles M. Baum is the CEO of Mirati Therapeutics, Inc."
        },
        {
            "question": "Where is Mirati Therapeutics headquartered?",
            "answer": "Mirati Therapeutics is headquartered in San Diego, California, USA."
        },
        {
            "question": "What is Mirati's lead product?",
            "answer": "Mirati's lead product is Krazati (adagrasib), which targets KRAS G12C mutations in cancer."
        },
        {
            "question": "When was Mirati Therapeutics founded?",
            "answer": "Mirati Therapeutics was founded in 2010."
        }
    ],
    "competitors": [
        "AMGN",
        "BMY",
        "REGN",
        "VRTX"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "MRK",
        "ABBV"
    ]
}